SIRT1 and COVID-19: In addition to the above-described effects, citicoline could potentially be used as a therapy for cases of cognitive decline related to COVID-19 because it has an anti-inflammatory action through inhibition of phospholipase 2 and upregulates the expression of SIRT1 protein levels in the brain, thus leading to improved neuronal plasticity and cognitive functioning [9]; furthermore, the drug has the potential to repair mitochondrial dysfunction and reduce oxidative damage [9,17].